

Supplementary Table 4. Baseline characteristics of mechanically ventilated COVID-19 patients

Variable	Before PS matching			After PS matching ^{a)}		
	Corticosteroid ≤ 14 days (n = 62)	Corticosteroid > 14 days (n=99)	<i>p</i> value	Corticosteroid ≤ 14 days (n = 57)	Corticosteroid >14 days (n = 57)	<i>p</i> value
Age, yr	71.5 (62–78)	68 (59–74)	0.012	71 (62–78)	66 (52–71)	0.001
Male	34 (54.8)	61 (61.6)	0.493	31 (54.4)	41 (71.9)	0.081
Body mass index, kg/m ²	24.9 (22.5–27.3)	25.7 (22.8–28.9)	0.039	25.0 (22.6–27.6)	26.8 (22.9–29.4)	0.023
Time from symptom onset to admission, days	5.5 (3–9)	6 (2–8)	0.739	6 (3–9)	6 (5–9)	0.504
Time from admission to intubation, days	2 (1–5)	2 (1–4)	0.569	2 (1–4)	2 (1–4)	0.460
Comorbidities	46 (74.2)	73 (73.7)	1.000	42 (73.7)	42 (73.7)	1.000
Hypertension	32 (51.6)	58 (58.6)	0.481	29 (50.9)	32 (56.1)	0.707
Diabetes	23 (37.1)	44 (44.4)	0.450	21 (36.8)	27 (47.4)	0.343
Chronic lung disease	3 (4.8)	1 (1.0)	0.160	3 (5.3)	0	0.243
Chronic kidney disease	3 (4.8)	2 (2.0)	0.374	2 (3.5)	2 (3.5)	1.000
Chronic liver disease	3 (4.8)	2 (2.0)	0.374	3 (5.3)	2 (3.5)	1.000
Cardiovascular disease	5 (8.1)	1 (1.0)	0.032	4 (7.0)	0	0.118
Cerebrovascular disease	4 (6.5)	7 (7.1)	1.000	4 (7.0)	4 (7.0)	1.000
Malignancy	6 (9.7)	8 (8.1)	0.950	6 (10.5)	5 (8.8)	1.000
Vital signs						
Systolic blood pressure, mmHg	131 (120–146)	140 (124–152)	0.082	130 (120–146)	144 (132–155)	0.013
Diastolic blood pressure, mmHg	76 (65–84)	78 (68–89)	0.117	77 (65–84)	78 (70–89)	0.151
Heart rate, /min	92 (76–105)	89 (76–102)	0.660	92 (76–105)	88 (78–102)	0.892
Respiratory rate, /min	21 (20–25)	22 (20–26)	0.627	21 (20–25)	20 (20–25)	0.522
Body temperature, °C	36.8 (36.5–37.4)	36.8 (36.5–37.6)	0.848	36.9 (36.5–37.4)	36.8 (36.4–37.4)	0.568
PaO ₂ /FiO ₂ at admission	133 (87–194)	108 (76–155)	0.097	138 (93–200)	104 (75–148)	0.040
Chest X-ray at admission						
Normal	1 (1.6)	2 (2.0)		1 (1.8)	1 (1.8)	
Unilateral	9 (14.5)	9 (9.1)		8 (14.0)	4 (7.0)	
Bilateral	23 (37.1)	45 (45.5)		21 (36.8)	28 (49.1)	
Multifocal	29 (46.8)	43 (43.4)		27 (47.4)	24 (42.1)	
Treatment						
Remdesivir	33 (53.2)	64 (64.6)	0.202	32 (56.1)	41 (71.9)	0.118
Vasopressor	27 (43.5)	53 (53.5)	0.284	26 (45.6)	38 (66.7)	0.038
Renal replacement therapy	15 (24.2)	20 (20.2)	0.688	14 (24.6)	10 (17.5)	0.491
Neuromuscular blocker	40 (64.5)	79 (79.8)	0.049	36 (63.2)	50 (87.7)	0.005
Prone positioning	5 (8.1)	17 (17.2)	0.161	5 (8.8)	13 (22.8)	0.072
ECMO	5 (8.1)	25 (25.3)	0.012	5 (8.8)	19 (33.3)	0.003
Maximal dose of corticosteroid, mg ^{b)}	32 (32–32)	64 (32–80)	< 0.001	32 (32–40)	64 (60–90)	< 0.001

Values are presented as median (interquartile range) or number (%).

COVID-19, coronavirus disease 2019; PS, propensity score; PaO₂, partial pressure of oxygen; FiO₂, fraction of inspired oxygen; ECMO, extracorporeal membrane oxygenation.

^{a)}Adjusted based on propensity score: age, sex, body mass index, time from admission to intubation, comorbidities, PaO₂/FiO₂, chest X-ray, remdesivir, vasopressor, renal replacement therapy, severity scale, and maximal dose of corticosteroids.

^{b)}Doses of each corticosteroid were converted to be equivalent to 1 mg of methylprednisolone.